



Liste des publications IUCT-O/CRCT

Décembre 2022

Version du 04 janvier 2023

(IF 2021)

1. Afferi, L., Lonati, C., Montorsi, F., Briganti, A., Necchi, A., Mari, A., Minervini, A., Tellini, R., Campi, R., Schulz, G.B., Black, P.C., di Trapani, E., de Cobelli, O., Karnes, R.J., Ahmed, M., Mir, M.C., Algarra, M.A., Rink, M., Zamboni, S., Mondini, F., Simeone, C., Antonelli, A., Tafuri, A., Krajewski, W., Małkiewicz, B., Xylinas, E., Soria, F., Sanchez Salas, R., Arora, A., Cathelineau, X., Hendricksen, K., Ammiwala, M., Borghesi, M., Chierigo, F., Teoh, J.Y.-C., Mattei, A., Albisinni, S., Roghmann, F., Roumigué, M., Bajeot, A.S., Maier, E., Aziz, A., Hurle, R., Contieri, R., Pradere, B., Carando, R., Poyet, C., Alvarez-Maestro, M., D'Andrea, D., Shariat, S.F., Moschini, M., European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group, 2022. **Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer**. Eur Urol Oncol 5, 722–725. <https://doi.org/10.1016/j.euo.2022.04.001> (cat A - IF : 8.208)
2. Aktas Samur, A., Fulciniti, M., Avet-Loiseau, H., Lopez, M.A., Derebail, S., Corre, J., Minvielle, S., Magrangeas, F., Moreau, P., Anderson, K.C., Parmigiani, G., Samur, M.K., Munshi, N.C., 2022. **In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors**. Blood Cancer J 12, 171. <https://doi.org/10.1038/s41408-022-00759-6> (cat B - IF : 9.812)
3. Algrin, C., Pérol, L., Chapiro, E., Baseggio, L., Maloum, K., Settegrana, C., Lesesve, J.-F., Siavellis, J., Delmer, A., Michallet, A.-S., Ferrant, E., Feugier, P., Tomowiak, C., Brion, A., Ghez, D., Fornecker, L.-M., Ivanoff, S., Struski, S., Sutton, L., Radford-Weiss, I., Eclache, V., Lefebvre, C., Leblond, V., Nguyen-Khac, F., Roos-Weil, D., 2022. **Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)**. Haematologica. <https://doi.org/10.3324/haematol.2022.282162> (cat A - IF : 11.047)
4. Baboudjian, M., Roubaud, G., Fromont, G., Gauthé, M., Beauval, J.-B., Barret, E., Brureau, L., Créhange, G., Dariane, C., Fiard, G., Roumigué, M., Ruffion, A., Rouprêt, M., Renard-Penna, R., Sargos, P., Ploussard, G., Prostate Cancer Committee of the French Association of Urology, 2022. **What is the ideal combination therapy in de novo, oligometastatic,**

castration-sensitive prostate cancer? World J Urol. <https://doi.org/10.1007/s00345-022-04239-1> (cat A - IF : 8.208)

5. Boden, A., Lusque, A., Lodin, S., Bourguoin, M., Mauries, V., Moreau, C., Fabre, A., Mounier, M., Poubanc, M., Caunes-Hilary, N., Filleron, T., 2022. **Study protocol of the TEC-ORL clinical trial: a randomized comparative phase II trial investigating the analgesic activity of capsaicin vs Laroxyl in head and neck Cancer survivors presenting with neuropathic pain sequelae.** BMC Cancer 22, 1260. <https://doi.org/10.1186/s12885-022-10348-2> (cat C - IF : 4.638)
6. Brahmi, M., Gaspar, N., Gantzer, J., Toulmonde, M., Boudou-Rouquette, P., Bompas, E., Firmin, N., Valentin, T., Cancel, M., Duffaud, F., Bertucci, F., Perrin, C., Dufresne, A., Marec-Bérard, P., Jean-Denis, M., Ray-Coquard, I., Le Loarer, F., Pierron, G., Tirode, F., Blay, J.-Y., Watson, S., 2022. **Patterns of care and outcome of CIC-rearranged sarcoma patients: A nationwide study of the French sarcoma group.** Cancer Med. <https://doi.org/10.1002/cam4.5539> (cat C - IF : 4.711)
7. Camus, V., Belot, A., Oberic, L., Sibon, D., Ghesquières, H., Thieblemont, C., Fruchart, C., Casasnovas, O., Michot, J.-M., Molina, T.J., Bosly, A., Joubert, C., Haioun, C., Nicolas-Virelizier, E., Feugier, P., Fitoussi, O., Delarue, R., Tilly, H., 2022. **Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.** Blood Adv 6, 6169–6179. <https://doi.org/10.1182/bloodadvances.2022007609> (cat B - IF : 7.637)
8. Canali, A., Corre, J., Riviere, B., Condom, P., Rieu, J.-B., 2022. **Monoclonal plasma cells with normal phenotype can lead to diagnosis of small B-cell lymphoma.** EJHaem 3, 1400–1401. <https://doi.org/10.1002/jha2.540> (cat NC)
9. Carausu, M., Carton, M., Diéras, V., Petit, T., Guiu, S., Gonçalves, A., Augereau, P., Ferrero, J.M., Levy, C., Ung, M., Desmoulins, I., Debled, M., Bachelot, T., Pistilli, B., Frenel, J.-S., Mailliez, A., Chevrot, M., Cabel, L., 2022. **Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.** JAMA Netw Open 5, e2247154. <https://doi.org/10.1001/jamanetworkopen.2022.47154> (cat A - IF : 13.453)
10. Colonna, M., Grosclaude, P., Bouvier, A.-M., Goungounga, J.A., Jooste, V., 2022. **Reply to “Survivorship experience: More than premature mortality from cancer.”** Cancer. <https://doi.org/10.1002/cncr.34581> (cat B - IF : 6.921)
11. Corrie, P., Meyer, N., Berardi, R., Guidoboni, M., Schlueter, M., Kolovos, S., Macabeo, B., Trouiller, J.-B., Laramée, P., 2022. **Erratum to “Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis”** [Cancer Treat. Rev. 110 (2022) 102463]. Cancer Treat Rev 112, 102495. <https://doi.org/10.1016/j.ctrv.2022.102495> (cat A - IF : 13.608)
12. Deluche, E., Marti, C., Jochum, F., Bendifallah, S., Azaïs, H., Deidier, J., Cockenpot, V., Menoux, I., Kissel, M., Balaya, V., Betrian, S., Mathevet, P., Chargari, C., Gouy, S., Genestie,

- C., Uzan, C., Devouassoux-Shisheboran, M., Guyon, F., Akladios, C., Body, N., Guani, B., Pour le groupe SFOG et SFOG campus, 2022. [**Application in France of the 2021 European recommendations on endometrial cancer**]. Bull Cancer S0007-4551(22)00428-3. <https://doi.org/10.1016/j.bulcan.2022.11.003> (*cat E - IF : 1.318*)
13. Dubucs, C., Chassaing, N., Khung-Savatovsky, S., Aziza, J., Courtade-Saïdi, M., 2022a. **Artifacts and main lesions in fetal ocular histology**. Morphologie S1286-0115(22)00201-6. <https://doi.org/10.1016/j.morpho.2022.08.002> (*cat NC*)
 14. Dubucs, C., Groussolles, M., Brazet, E., Courtade-Saïdi, M., Van Acker, N., Ousselin, J., Pasquier, C., Aziza, J., 2022b. Fetal death and placental lesions after two COVID-19 episodes in single pregnancy in unvaccinated woman. Ultrasound Obstet Gynecol 60, 814–816. <https://doi.org/10.1002/uog.26029> (*cat A - IF : 8.678*)
 15. Dulucq, S., Nicolini, F.E., Rea, D., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Coiteux, V., Lenain, P., Rigal-Huguet, F., Liu, J., Guerci-Bresler, A., Legros, L., Ianotto, J.-C., Gardembas, M., Turlure, P., Dubruille, V., Rousselot, P., Martiniuc, J., Jardel, H., Johnson-Ansah, H., Joly, B., Henni, T., Cayssials, E., Zunic, P., Berger, M.G., Villemagne, B., Robbesyn, F., Morisset, S., Mahon, F.-X., Etienne, G., 2022. **Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial**. Haematologica 107, 2859–2869. <https://doi.org/10.3324/haematol.2022.280811> (*cat A - IF : 11.047*)
 16. Fraissinet, F., Oumar, A.A., Seraissol, P., Cere, M.C., Lavit, M., Chatelut, E., Gandia, P., 2022. **Method validation and clinical application for the quantification of lopinavir, efavirenz, and ritonavir in breast milk using liquid chromatography tandem mass spectrometry**. J Mass Spectrom 57, e4897. <https://doi.org/10.1002/jms.4897> (*cat D - IF : 2.394*)
 17. Galceran, J., Parada, D., Eden, M., Tumino, R., Warren, A.Y., Martos, C., Neamtii, L., Visser, O., Daubisse-Marliac, L., 2022. **The 2022 ENCR Recommendations on recording and reporting of urothelial tumours of the urinary tract**. Front Oncol 12, 1046239. <https://doi.org/10.3389/fonc.2022.1046239> (*cat C - IF : 5.738*)
 18. Gallois, Y., Siegfried, A., Dupin-Deguine, D., Deguine, O., 2022. **Bilateral tympanic myxoma: A CARE case report**. Eur Ann Otorhinolaryngol Head Neck Dis S1879-7296(22)00115-6. <https://doi.org/10.1016/j.anorl.2022.10.002> (*cat C - IF : 2.665*)
 19. Garassino, M.C., Mazieres, J., Reck, M., Chouaid, C., Bischoff, H., Reinmuth, N., Cove-Smith, L., Mansy, T., Cortinovis, D., Migliorino, M.R., Delmonte, A., Sánchez, J.G., Chara Velarde, L.E., Bernabe, R., Paz-Ares, L., Perez, I.D., Trunova, N., Foroutanpour, K., Faivre-Finn, C., 2022. **Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial**. J Thorac Oncol 17, 1415–1427. <https://doi.org/10.1016/j.jtho.2022.07.1148> (*cat A - IF : 20.121*)
 20. Héluain, V., Prévot, G., Cabarrou, B., Calvayrac, O., Taranchon-Clermont, E., Didier, A., Tabourier-Gouin, S., Milia, J., Mazières, J., 2022. **Clinical and molecular analysis of lung**

cancers associated with fibrosing interstitial lung disease. *Respir Med Res* 83, 100946. <https://doi.org/10.1016/j.resmer.2022.100946> (*cat D - IF : 3.149*)

- 21.** Jiao, Y., Truong, T., Eon-Marchais, S., Mebirouk, N., Caputo, S.M., Dondon, M.-G., Karimi, M., Le Gal, D., Beauvallet, J., Le Floch, É., Dandine-Roulland, C., Bacq-Daian, D., Olaso, R., Albuisson, J., Audebert-Bellanger, S., Berthet, P., Bonadona, V., Buecher, B., Caron, O., Cavaillé, M., Chiesa, J., Colas, C., Collonge-Rame, M.-A., Coupier, I., Delnatte, C., De Pauw, A., Dreyfus, H., Fert-Ferrer, S., Gauthier-Villars, M., Gesta, P., Giraud, S., Gladieff, L., Golmard, L., Lasset, C., Lejeune-Dumoulin, S., Léoné, M., Limacher, J.-M., Lortholary, A., Luporsi, É., Mari, V., Maugard, C.M., Mortemousque, I., Mouret-Fourme, E., Nambot, S., Noguès, C., Popovici, C., Prieur, F., Pujol, P., Sevenet, N., Sobol, H., Toulas, C., Uhrhammer, N., Vaur, D., Venat, L., Boland-Augé, A., Guénel, P., Deleuze, J.-F., Stoppa-Lyonnet, D., Andrieu, N., Lesueur, F., 2022. **Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.** *Eur J Cancer* 179, 76–86. <https://doi.org/10.1016/j.ejca.2022.11.007> (*cat B - IF : 10.002*)
- 22.** Jodkowska, K., Pancaldi, V., Rigau, M., Almeida, R., Fernández-Justel, J.M., Graña-Castro, O., Rodríguez-Acebes, S., Rubio-Camarillo, M., Carrillo-de Santa Pau, E., Pisano, D., Al-Shahrour, F., Valencia, A., Gómez, M., Méndez, J., 2022. **3D chromatin connectivity underlies replication origin efficiency in mouse embryonic stem cells.** *Nucleic Acids Res* 50, 12149–12165. <https://doi.org/10.1093/nar/gkac1111> (*cat A - IF : 19.16*)
- 23.** Kacperczyk-Bartnik, J., Bizzarri, N., Angeles, M.A., Theofanakis, C., Shushkevich, A.B., Strojna, A.N., Pletnev, A., Nikolova, T., Ledermann, J., Vergote, I., 2022. **Best original research presented at the 23rd European Congress on Gynaecological Oncology-Best of ESGO 2022.** *Int J Gynecol Cancer* ijgc–2022–004184. <https://doi.org/10.1136/ijgc-2022-004184> (*cat B - IF : 4.661*)
- 24.** Laloï, L., Billotey, N.C., Dumas, P.-Y., Paul, F., Villate, A., Simand, C., Fornecker, L., Puisset, F., Bertoli, S., Simonet, M.B., Laribi, K., Houyou, D., Santagostino, A., Michel, C., Guepin, G.R., Guerineau, E., Tabrizi, R., Hunault, M., Giltat, A., Kaphan, E., Bulaboïs, C., Cartet, E., Rocher, C., Lachenal, F., Morisset, S., Récher, C., Pigneux, A., Belhabri, A., Michallet, M., Michallet, A.-S., 2022. **Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.** *Cancer Med.* <https://doi.org/10.1002/cam4.5459> (*cat C - IF : 4.711*)
- 25.** Malka, D., Girard, N., Smadja, D.M., Chevreau, C., Culine, S., Lesur, A., Rouzier, R., Rozet, F., Spano, J.-P., Blay, J.-Y., 2022. **[Prophylaxis and management of cancer-associated thrombosis: Practical issues about anticoagulant use].** *Bull Cancer* S0007-4551(22)00424–6. <https://doi.org/10.1016/j.bulcan.2022.10.008> (*cat E - IF : 1.318*)
- 26.** Marczyk, A., O'Brien, B., Tremblay, P., Woisard, V., Ghio, A., 2022. **Correlates of vowel clarity in the spectrotemporal modulation domain: Application to speech impairment evaluation.** *J Acoust Soc Am* 152, 2675. <https://doi.org/10.1121/10.0015024> (*cat C - IF : 2.482*)

27. Masson, E., Ewers, M., Paliwal, S., Kume, K., Scotet, V., Cooper, D.N., Rebours, V., Buscail, L., Rouault, K., GREPAN (Genetic REsearch on PANcreatitis) Study Group, Abrantes, A., Aguilera Munoz, L., Albouys, J., Alric, L., Amiot, X., Archambeaud, I., Audiau, S., Bastide, L., Baudon, J., Bellaiche, G., Bellon, S., Bertrand, V., Bideau, K., Billiemaz, K., Billioud, C., Bonnefoy, S., Borderon, C., Bournet, B., Breton, E., Brugel, M., Buscail, L., Cadiot, G., Camus, M., Carpentier-Pourquier, M., Chamouard, P., Chaput, U., Chen, J.-M., Cholet, F., Ciocan, D.M., Clavel, C., Coffin, B., Coimet-Berger, L., Coscinea, S., Creveaux, I., Culetto, A., Daboussi, O., De Mestier, L., Degand, T., D'engremont, C., Denis, B., Dermine, S., Desgrippes, null, Drouet D'Aubigny, A., Enaud, R., Fabre, A., Férec, C., Gargot, D., Gelsi, E., Gentilcore, E., Gincul, R., Ginglinger-Favre, E., Giovannini, M., Gomercic, C., Gondran, H., Grainville, T., Grandval, P., Grasset, D., Grimaldi, S., Grimbert, S., Hagege, H., Heissat, S., Hentic, O., Herber-Mayne, A., Hervouet, M., Hoibian, S., Jacques, J., Jais, B., Kaassis, M., Koch, S., Lacaze, E., Lacroute, J., Lamireau, T., Laurent, L., Le Guillou, X., Le Rhun, M., Leblanc, S., Levy, P., Lievre, A., Lorenzo, D., Maire, F., Marcel, K., Masson, E., Mauillon, J., Morgant, S., Moussata, D., Muller, N., Nambot, S., Napoleon, B., Olivier, A., Pagenault, M., Pelletier, A.-L., Pennec, O., Pinard, F., Pioche, M., Prost, B., Queneherve, L., Rebours, V., Reboux, N., Rekik, S., Riachi, G., Rohmer, B., Roquelaure, B., Rosa Hezode, I., Rostain, F., Saurin, J.-C., Servais, L., Stan-luga, R., Subtil, C., Tanneche, J., Texier, C., Thomassin, L., Tougeron, D., Vuitton, L., Wallenhorst, T., Wangerme, M., Zanalidi, H., Zerbib, F., Bhaskar, S., Kikuta, K., Rao, G.V., Hamada, S., Reddy, D.N., Masamune, A., Chandak, G.R., Witt, H., Férec, C., Chen, J.-M., 2022. **The PRSS3P2 and TRY7 deletion copy number variant modifies risk for chronic pancreatitis.** Pancreatology S1424-3903(22)00822–5. <https://doi.org/10.1016/j.pan.2022.11.013> (cat C - IF : 3.977)
28. McKenzie, B. & Valitutti, S., 2022. **Resisting T cell attack: tumor-cell-intrinsic defense and reparation mechanisms.** Trends Cancer S2405-8033(22)00264–3. <https://doi.org/10.1016/j.trecan.2022.12.003> (cat A - IF : 19.161)
29. Mohty, M., Blaise, D., Peffault de Latour, R., Labopin, M., Bourhis, J.H., Bruno, B., Ceballos, P., Detrait, M., Gandemer, V., Huynh, A., Izadifar-Legrand, F., Jubert, C., Labussière-Wallet, H., Lebon, D., Maury, S., Paillard, C., Pochon, C., Renard, C., Rialland, F., Schneider, P., Sirvent, A., Asubonteng, K., Guindeuil, G., Yakoub-Agha, I., Dalle, J.-H., 2022. **Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study.** Bone Marrow Transplant. <https://doi.org/10.1038/s41409-022-01900-6> (cat C - IF : 5.174)
30. Nikolaou, V.A., Apalla, Z., Carrera, C., Fattore, D., Sollena, P., Riganti, J., Segura, S., Freitas-Martinez, A., Lallas, K., Romano, M.C., Oikonomou, C., Starace, M., Dimopoulos, M.A., Kyrgidis, A., Lazaridou, E., Giavedoni, P., Annunziata, M.C., Peris, K., Echeverría, M., Lopez-Tujillo, E., Syrigos, K., Papageorgiou, C., Podlipnik, S., Fabbrocini, G., Torre, A.C., Kemanetzi, C., Villa-Crespo, L., Lallas, A., Stratigos, A.J., Sibaud, V., 2022. **Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.** Br J Dermatol 187, 962–969. <https://doi.org/10.1111/bjd.21781> (cat A - IF : 11.113)

31. Othman, J., Meggendorfer, M., Tiacchi, E., Thiede, C., Schlenk, R.F., Dillon, R., Stasik, S., Venanzi, A., Bertoli, S., Delabesse, E., Dumas, P.-Y., Pigneux, A., Bidet, A., Gilkes, A.F., Thomas, I., Voso, M.T., Rambaldi, A., Brunetti, L., Perriello, V.M., Andresen, V., Gjertsen, B.T., Martelli, M.P., Récher, C., Röllig, C., Bornhäuser, M., Serve, H., Müller-Tidow, C., Baldus, C.D., Haferlach, T., Russell, N.H., Falini, B., 2022. **Overlapping features of therapy-related and de novo NPM1-mutated AML.** Blood blood.2022018108. <https://doi.org/10.1182/blood.2022018108> (cat A - IF : 25.476)
32. Paiva, B., San-Miguel, J., Avet-Loiseau, H., 2022. **MRD in multiple myeloma: does CR really matter?** Blood 140, 2423–2428. <https://doi.org/10.1182/blood.2022016170> (cat A - IF : 25.476)
33. Perl, A.E., Larson, R.A., Podoltsev, N.A., Strickland, S., Wang, E.S., Atallah, E., Schiller, G.J., Martinelli, G., Neubauer, A., Sierra, J., Montesinos, P., Recher, C., Yoon, S.-S., Maeda, Y., Hosono, N., Onozawa, M., Kato, T., Kim, H.-J., Hasabou, N., Nuthethi, R., Tiu, R., Levis, M.J., 2022. **Outcomes in Patients With FLT3-Mutated R/R AML Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib Versus Salvage Chemotherapy.** Transplant Cell Ther S2666-6367(22)01832–2. <https://doi.org/10.1016/j.jtct.2022.12.006> (cat B - IF : 5.609)
34. Ploussard, G., Rozet, F., Roubaud, G., Stanbury, T., Sargos, P., Roupert, M., 2022. **Chromogranin A: a useful biomarker in castration-resistant prostate cancer.** World J Urol. <https://doi.org/10.1007/s00345-022-04248-0> (cat C - IF : 3.661)
35. Ponzo, M., Debesset, A., Cossutta, M., Chalabi-Dchar, M., Houppe, C., Pilon, C., Nicolas-Boluda, A., Meunier, S., Raineri, F., Thiolat, A., Nicolle, R., Maione, F., Brundu, S., Cojocar, C.F., Bouvet, P., Bousquet, C., Gazeau, F., Tournigand, C., Courty, J., Giraudo, E., Cohen, J.L., Cascone, I., 2022. **Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression.** Cancers 2022, 14, 4265. Cancers (Basel) 14, 6160. <https://doi.org/10.3390/cancers14246160> (cat A - IF : 25.476)
36. Poumeaud, F., Fontanier, N., Dion, R., Mathevet, N., Cointault, O., Uro-Coste, E., Marty, C., Dalenc, F., Girardie, P. & Rataboul, A., 2022. **Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: A case report.** Front Oncol 12, 1026434. <https://doi.org/10.3389/fonc.2022.1026434> (cat C - IF : 5.738)
37. Quillien, L., Buscail, L., Cordelier, P., 2022. **Pancreatic cancer cell and gene biotherapies; past, present and future.** Hum Gene Ther. <https://doi.org/10.1089/hum.2022.210> (cat B - IF : 4.793)
38. Rieu, J.-B., Canali, A., Vergez, F., Bain, B.J., 2022. **Diagnosis of histiocytic sarcoma by bone marrow aspiration.** Am J Hematol. <https://doi.org/10.1002/ajh.26815> (cat A - IF : 13.265)
39. Rigault, E., Lacas, B., Glehen, O., Smith, D., Dupont-Bierre, E., Guimbaud, R., Malka, D., Boige, V., Fuerea, A., Pignon, J.-P., Ducreux, M., 2022. **Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II**

multicentric trial in second-line treatment. Cancer Treat Res Commun 34, 100674. <https://doi.org/10.1016/j.ctarc.2022.100674> (*cat NC*)

40. Rossi, C., André, M., Dupuis, J., Morschhauser, F., Joly, B., Lazarovici, J., Ghesquières, H., Stamatoullas, A., Nicolas-Virelizier, E., Feugier, P., Gac, A.-C., Moatti, H., Fornecker, L.-M., Deau, B., Joubert, C., Fortpied, C., Raemaekers, J., Federico, M., Kanoun, S., Meignan, M., Traverse-Glehen, A., Cottreau, A.-S., Casasnova, R.-O., 2022. **High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline.** Haematologica 107, 2897–2904. <https://doi.org/10.3324/haematol.2021.280004> (*cat A - IF : 11.047*)
41. Sakata, D., Hirayama, R., Shin, W.-G., Belli, M., Tabocchini, M.A., Stewart, R.D., Belov, O., Bernal, M.A., Bordage, M.-C., Brown, J.M.C., Dordevic, M., Emfietzoglou, D., Francis, Z., Guatelli, S., Inaniwa, T., Ivanchenko, V., Karamitros, M., Kyriakou, I., Lampe, N., Li, Z., Meylan, S., Michelet, C., Nieminen, P., Perrot, Y., Petrovic, I., Ramos-Mendez, J., Ristic-Fira, A., Santin, G., Schuemann, J., Tran, H.N., Villagrasa, C., Incerti, S., 2022. **Prediction of DNA rejoining kinetics and cell survival after proton irradiation for V79 cells using Geant4-DNA.** Phys Med 105, 102508. <https://doi.org/10.1016/j.ejmp.2022.11.012> (*cat D - IF : 3.119*)
42. Sandbank, J., Bataillon, G., Nudelman, A., Krasnitsky, I., Mikulinsky, R., Bien, L., Thibault, L., Albrecht Shach, A., Sebag, G., Clark, D.P., Laifenfeld, D., Schnitt, S.J., Linhart, C., Vecsler, M., Vincent-Salomon, A., 2022. **Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies.** NPJ Breast Cancer 8, 129. <https://doi.org/10.1038/s41523-022-00496-w> (*cat B - IF : 7.519*)
43. Selves, J., 2022. [Molecular profiling in daily practice for cholangiocarcinoma]. Ann Pathol 42, 6S5–6S7. [https://doi.org/10.1016/S0242-6498\(22\)00212-7](https://doi.org/10.1016/S0242-6498(22)00212-7) (*cat E - IF : 0.411*)
44. Solomon, B.J., Bauer, T.M., Mok, T.S.K., Liu, G., Mazieres, J., de Marinis, F., Goto, Y., Kim, D.-W., Wu, Y.-L., Jassem, J., López, F.L., Soo, R.A., Shaw, A.T., Polli, A., Messina, R., Iadeluca, L., Toffalorio, F., Felip, E., 2022. **Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.** Lancet Respir Med S2213-2600(22)00437–4. [https://doi.org/10.1016/S2213-2600\(22\)00437-4](https://doi.org/10.1016/S2213-2600(22)00437-4) (*cat A - IF : 102.642*)
45. Syrykh, C., Chaouat, C., Poullot, E., Amara, N., Fataccioli, V., Parrens, M., Traverse-Glehen, A., Molina, T.-J., Xerri, L., Martin, L., Dubois, R., Lacheretz-Szablewski, V., Copin, M.-C., Moreau, A., Chenard, M.-P., Cabarrou, B., Lusque, A., Gaulard, P., Brousset, P., Laurent, C., 2022. **Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey.** Blood 140, 2573–2583. <https://doi.org/10.1182/blood.2022015520> (*cat A - IF : 25.476*)
46. Tao, Y., Biau, J., Sun, X.S., Sire, C., Martin, L., Alfonsi, M., Prevost, J.B., Modesto, A., Lafond, C., Tourani, J.M., Miroir, J., Kaminsky, M.C., Coutte, A., Liem, X., Chautard, E., Vauleon, E., Drouet, F., Ruffier, A., Ramee, J.F., Waksi, G., Péchery, A., Wanneveich, M., Guigay, J., Aupérin, A., Bourhis, J., 2022. **Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck**

unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Ann Oncol S0923-7534(22)04197-7. <https://doi.org/10.1016/j.annonc.2022.10.006> (cat A - IF : 51.769)

47. Tsaour, I., van den Bergh, R.C.N., Soeterik, T., Thomas, A., Brandt, M.P., Zattoni, F., Dal Moro, F., Morlacco, A., Collavino, J., Ploussard, G., Surcel, C., Mirvald, C., Carmona, O., Rosenzweig, B., Ruckes, C., Heisinger, T., Heidegger, I., Gandaglia, G., Dotzauer, R., European Association of Urology Young Academic Urologists Prostate Cancer Working Party, 2022. **Predictors of Unfavorable Pathology in Patients with Incidental (pT1a-T1b) Prostate Cancer.** Eur Urol Focus 8, 1599–1606. <https://doi.org/10.1016/j.euf.2022.03.009> (cat B - IF : 5.952)
48. Vieira-Serna, S., Viveros-Carreño, D., Rodríguez, J., Grillo-Ardila, C.F., Angeles, M.A., Guerrero, E., Sanabria, D., Pareja, R., 2022. **Preoperative brachytherapy for early-stage cervical cancer: Systematic review and meta-analysis.** Gynecol Oncol 169, 4–11. <https://doi.org/10.1016/j.ygyno.2022.11.009> (cat B - IF : 5.304)
49. Younan, N., Soussain, C., Choquet, S., Cassoux, N., Touitou, V., Schmitt, A., Chinot, O., Oberic, L., Damaj, G., Houot, R., Ghesquière, H., Laribi, K., Ahle, G., Taillandier, L., Paillassa, J., Gyan, E., Jardin, F., Delwail, V., Marolleau, J.-P., Tempescul, A., Agapé, P., Bourniquel, M., Vacheret, F., Jdid, I., Le Garff-Tavernier, M., Malaise, D., Alentorn, A., Xuan, K.H., Houillier, C., 2022. **Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study.** Hematol Oncol 40, 976–986. <https://doi.org/10.1002/hon.3044> (cat C - IF : 4.85)



